Patterns Of Hedgehog Inhibitor (HHI) Treatment Interruptions and Reinitiations Among Patients with Basal Cell Carcinoma (BCC) in Real-World Clinical Practice

Main Article Content

Jessica Jalbert
Chieh-I Chen
Ning Wu
Matthew Fury
Wenzhen Ge
Emily Ruiz

Keywords

Skin Cancer, Basal cell Carcinoma, Hedgehog Inhibitor, Real-World

Abstract

Abstract not available.

References

1. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

2. Lear JT et al. Br J Cancer. 2014;111:1476–1481.

3. Kudchadkar R et al. Semin Oncol. 2012;39:139–144.

4. American Cancer Society. Treating basal cell carcinoma; 2019. Available at: https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/treating/basal-cell-carcinoma.html. [Accessed July 24, 2020].

5. Trakatelli M et al. Eur J Dermatol. 2014;24:312–329.

6. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: basal cell skin cancer version 1.2020; 2019. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. [Accessed June 2, 2020].

7. Cancer Council Australia/Australian Cancer Network. Basal cell carcinoma, squamous cell carcinoma (and related lesions) – a guide to clinical management in Australia; 2008; 2008. Available at: https://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/Basal_cell_carcinoma_Squamous_cell_carcinoma_Guide_Nov_2008-Final_with_Corrigendums.pdf. [Accessed July 24, 2020].

8. Goldenberg G et al. J Am Acad Dermatol. 2016;75:957–966.

9. Sekulic A et al. J Am Acad Dermatol. 2015;72:1021–1026 e1028.

10. Basset-Seguin N et al. Eur J Cancer. 2017;86:334–348.